Intake of Polyunsaturated fatty acids and vitamin E reduce the risk of developing ALS


J. Neurol. Neurosurg. Psychiatry published online 28 Apr 2006;
doi:10.1136/jnnp.2005.083378

Updated information and services can be found at:
http://jnnp.bmjjourrnals.com/cgi/content/abstract/jnnp.2005.083378v2

Rapid responses
One rapid response has been posted to this article, which you can access for free at:
http://jnnp.bmjjourrnals.com#responses
You can respond to this article at:

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

Online First contains unedited articles in manuscript form that have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Online First articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Online First articles must include the digital object identifier (DOIs) and date of initial publication.

To order reprints of this article go to:
http://www.bmjjourrnals.com/cgi/reprintform
To subscribe to Journal of Neurology, Neurosurgery, and Psychiatry go to:
http://www.bmjjourrnals.com/subscriptions/
Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis


Background: To assess whether the premorbid dietary intake of fatty acids, cholesterol, glutamate or antioxidants was associated with the risk of developing amyotrophic lateral sclerosis (ALS).

Methods: Patients referred to our clinic during 2001–2002, who had definite, probable or possible ALS according to El Escorial criteria, without a familial history of ALS, were asked to participate in a case–control study (132 patients and 220 healthy controls). A food-frequency questionnaire was used to assess dietary intake for the nutrients of interest. Multivariate logistic regression analysis was performed with adjustment for confounding factors (sex, age, level of education, energy intake, body mass index and smoking).

Results: A high intake of polyunsaturated fatty acid (PUFA) and vitamin E was significantly associated with a reduced risk of developing ALS (PUFA: odds ratio (OR) = 0.4, 95% confidence interval (CI) = 0.2 to 0.7, \( p = 0.001 \); vitamin E: OR = 0.4, 95% CI = 0.2 to 0.7, \( p = 0.001 \)). PUFA and vitamin E appeared to act synergistically, because in a combined analysis the trend OR for vitamin E was further reduced from 0.67 to 0.37 (\( p = 0.02 \)), and that for PUFA from 0.60 to 0.26 (\( p = 0.005 \)), with a significant interaction term (\( p = 0.03 \)). The intake of flavonols, lycopene, vitamin C, vitamin B₂, glutamate, calcium or phytoestrogens was not associated with the risk of developing ALS.

Conclusion: A high intake of PUFAs and vitamin E is associated with a 50–60% decreased risk of developing ALS, and these nutrients appear to act synergistically.
other two by controls. Every patient was asked to approach two persons who fulfilled the following criteria:

- should not be their spouse or partner
- should preferably not differ from them in age by more than 3 years
- should preferably be of the same sex.

Of 264 controls, 220 (83%) returned their questionnaires. All questionnaires remained anonymous, and all data were entered in a blinded fashion.

**Questionnaire**

The questionnaire was divided into two sections: the first section contained questions on age, sex, level of education, smoking and anthropometrical characteristics; the second section consisted of questions on food frequency. Patients were asked to recall their dietary habits during the period 1 year before the onset of muscle weakness or bulbar signs, to avoid a possible influence of subclinical disease on the factors of interest. Patients had to disclose this reference year to their controls, who had to report their dietary habits in the same reference year.

The food-frequency questionnaire had 104 questions that were validated for the intake of total energy, total fat, fatty acids and cholesterol. The questionnaire was validated against linoleic acid concentrations in erythrocytes and adipose tissue as biomarkers of intake. These biomarkers were shown to be representative of long-term intake of fatty acids, as the half-life of linoleic acid in adipose tissue is approximately 680 days. The results of the questionnaire, therefore, are representative of a longer period of food intake. Considering the hypotheses of this study, the questionnaire was extended with questions on the dietary intake of glutamate, flavonoids, lycopene, vitamin B2, vitamin C, vitamin E, calcium and phytoestrogens. Therefore, 37 items were added according to a systematic procedure. Food items for the original questionnaire were chosen on the basis of the data of the Dutch National Food Consumption Survey of 1992. Data regarding vitamin C were also available from this survey, but other sources were used for the remaining nutrients: the national survey of 1987–1988; national reports by TNO Nutrition and Food Research and the Dutch Food Composition Tables (Nevo) for calcium, vitamin B2 and vitamin E; publications on flavonoids; the US Department of Agriculture table for phytoestrogens (isoflavones); publications on glutamate and monosodium glutamate; and the US Department of Agriculture table for lycopene. The 37 items that were added to the questionnaire on the basis of these sources accounted for at least 95% of the intake of a specific factor.

If questionnaires showed inconsistencies or if data were missing, the concerned were contacted by a nutritionist and asked for clarification. All questionnaires remained anonymous, and persons other than the nutritionist entered all the data in a blinded fashion.

**Statistical analysis**

Differences in categorical factors between patients and controls were determined by the χ² test. Differences in continuous variables were computed by using the Mann–Whitney U test (characteristics of patients and controls) and Student’s t test (univariate nutrient comparison). To obtain nutrient data that were not correlated to total energy intake, the energy-adjusted values were calculated according to the residual method. Nutrient data were categorised into tertiles based on the data of controls, and multivariate logistic regression was used to determine independent ORs for the association between intake of nutrients and ALS. tertile being the reference category. These three-level variables were also entered into the model as continuous variables to determine whether there was a linear trend. The multivariate model always included the following possible confounders: sex, age (at onset for patients, current age for controls), level of education (low, middle, high), smoking (never, ever, current) and (premorbid) BMI.

If nutrients were markedly associated with ALS and biological interaction could be hypothesised, the interaction between these nutrients was tested by entering both nutrients and their product into the multivariate model. We also carried out an exploratory analysis to test the possible association between clinical features (age at onset and duration of disease) and those nutrients that were independently associated with the risk of developing ALS. Cox regression analysis was used to determine the independent association between the intake of nutrients and age at onset of ALS adjusting for the above-mentioned confounders and type of onset. The same procedure was used to determine the independent association between intake of nutrients and duration of disease, additionally adjusting for age at onset and type of onset.

All tests were two-sided, and a p<0.05 was considered to be significant.

**RESULTS**

**Characteristics of patients and controls**

Table 1 shows the characteristics of patients and controls, including the main potential confounding factors for the relationship between nutrient intake and ALS.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients with ALS (n = 132)</th>
<th>Controls (n = 220)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (range)*</td>
<td>58 (25–79)</td>
<td>59 (28–81)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>89 (67)</td>
<td>136 (65)</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>43 (33)</td>
<td>73 (35)</td>
</tr>
<tr>
<td>Site of onset, n (%)</td>
<td>Spinal 105 (79)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bulbar 27 (21)</td>
<td></td>
</tr>
<tr>
<td>El Escorial category, n (%)</td>
<td>Possible 29 (22)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probable 79 (60)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Definite 24 (18)</td>
<td></td>
</tr>
<tr>
<td>Education, n (%)</td>
<td>Low 46 (35)</td>
<td>64 (31)</td>
</tr>
<tr>
<td></td>
<td>Middle 44 (33)</td>
<td>62 (30)</td>
</tr>
<tr>
<td></td>
<td>High 42 (32)</td>
<td>82 (39)</td>
</tr>
<tr>
<td>Relationship with patient, n (%)</td>
<td>106 (51)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Direct family of partner</td>
<td>65 (31)</td>
</tr>
<tr>
<td></td>
<td>Neighbour 11 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Partner 8 (4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Direct family of patient</td>
<td>8 (4)</td>
</tr>
<tr>
<td></td>
<td>Therapist or care giver</td>
<td>6 (3)</td>
</tr>
<tr>
<td></td>
<td>Colleague 4 (2)</td>
<td></td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>Never 42 (32)</td>
<td>60 (30)</td>
</tr>
<tr>
<td></td>
<td>Ever 61 (46)</td>
<td>101 (51)</td>
</tr>
<tr>
<td></td>
<td>Current 29 (22)</td>
<td>39 (20)</td>
</tr>
<tr>
<td></td>
<td>Premorbid or current BMI, median, kg/m² (range)$</td>
<td>25 (18–50)</td>
</tr>
<tr>
<td></td>
<td>Obese (≥30)</td>
<td>9 (7)</td>
</tr>
<tr>
<td></td>
<td>Overweight (25–30)</td>
<td>60 (46)</td>
</tr>
<tr>
<td></td>
<td>Normal or underweight (&lt;25)</td>
<td>63 (48)</td>
</tr>
</tbody>
</table>

BMI, body mass index.

*Age at onset of disease for patients and current age for controls.
†For patients in the year before the onset of disease.
‡For patients, premorbid BMI; for controls, current BMI; in some cases, the sum of the data is not equivalent to the total of patients or controls, as some values are missing.
A representative sample of patients with ALS was obtained with respect to sex, although a younger age at onset and a relative predominance of patients with spinal onset in our sample suggest some referral bias as compared with a recent population-based study.27

Patients and controls were not markedly different with regard to potential confounders (age, $p = 0.21$; sex, $p = 0.66$; education, $p = 0.37$; smoking, $p = 0.73$; BMI, $p = 0.72$). All analyses were adjusted for age and other potential confounding factors (gender, level of education, BMI and smoking).

### Daily nutrient intake and risk of developing ALS

Table 2 compares the mean, energy-adjusted daily intake of nutrients between patients and controls. Premorbid total energy intake was similar in the two groups, which is in accordance with similar premorbid BMI levels (table 1). Univariate analysis of total cholesterol intake showed a higher intake in patients with ALS, although this difference did not reach significance. Intake of polyunsaturated fatty acid (PUFA) and vitamin E was noticeably lower in patients with ALS than in controls. Premorbid daily intake of dietary supplements (mostly combinations of several nutrients) was also assessed, but did not differ significantly between patients and controls.

Figure 1 shows the adjusted ORs for the relationship between energy-adjusted intake of nutrients and ALS. Multivariate analysis showed that the inverse association of intake of PUFAs and vitamin E with ALS was again highly significant. The highest tertile of daily PUFA intake (>32 g) was associated with a 60% lower risk of ALS compared with the lowest tertile (<25 g). The second tertile of vitamin E (18–22 mg) was associated with a 50% lower risk of ALS; the highest tertile of vitamin E intake (45 mg) was associated with a 50% lower risk of ALS compared with the lowest tertile (<18 mg). The association with cholesterol intake was not significant (highest tertile with the lowest tertile OR = 1.6, 95% CI = 0.9 to 2.7, $p = 0.11$).

Interaction analysis showed that the ORs for vitamin E were further reduced from 0.67 to 0.37 ($p = 0.02$), and for PUFA from 0.60 to 0.26 ($p = 0.005$), with a significant interaction term ($p = 0.03$).

Flavonols, lycopene, vitamin B2 (not shown) and vitamin C did not show any significant association. Analysis of glutamate, calcium and phytoestrogens all yielded adjusted $p>0.73$.

### Daily nutrient intake and clinical features

No salient association between PUFA and vitamin E intake and age at onset or duration of disease was found with multivariate Cox regression analysis. PUFA and duration of disease: hazard ratio (HR) = 0.94, 95% CI = 0.7 to 1.3, $p = 0.72$. PUFA and age at onset: HR = 0.94, 95% CI = 0.7 to 1.2, $p = 0.63$. Vitamin E and duration of disease: HR = 1.2, 95% CI = 0.9 to 1.7, $p = 0.18$. Vitamin E and age at onset: HR = 0.93, 95% CI = 0.7 to 1.2, $p = 0.52$.

## DISCUSSION

We investigated the association between intake of nutrients and the risk of developing ALS, as we hypothesised that daily nutrient intake can modify observed pathological processes in ALS, including oxidative stress, mitochondrial dysfunction, apoptosis, inflammation and glutamate excitotoxicity. This study showed that higher premorbid dietary intake of PUFAs and vitamin E was associated with a 50–60% decreased risk of developing ALS. These associations were independent of possible confounding factors and total energy intake.

The finding that a higher intake of PUFAs appeared to decrease the risk of developing ALS may be in accordance with the results of studies in patients with other primarily neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease.12 28 Omega 3 PUFAs—eicosapentanoic acid, docosahexanoic acid and alpha-linolenic acid—in particular, have been shown to protect against cardiovascular disease and Alzheimer’s disease.29 In contrast, omega 6 fatty acids—linoleic acid—have opposite mechanisms of action.28 Arachidonic acid—derived from linoleic acid and eicosapentanoic acid—compete for the cyclooxygenase enzyme for conversion into prostaglandins. The prostaglandins derived from omega 6 are proinflammatory and those derived from omega 3 are anti-inflammatory.28 Inflammation and upregulation of cyclooxygenase have both been described in ALS.10 One previous study, however, found an association between a higher intake of PUFAs and a higher risk of developing ALS.4 The fact that the current food-frequency questionnaire was validated specifically for fat and cholesterol may partially explain this discrepancy.31 Also, because neither study differentiated between omega 3 and omega 6 PUFAs, differences between an American and European study population in consumption of specific foodstuffs that contain predominantly omega 3 (fish, dark green leafy vegetables) or omega 6 (cereals, whole-grain bread, baked goods, fried foods) PUFAs may also have contributed to these discrepancies.

Another possible mechanism of action of PUFAs is direct neuroprotection through attenuation of glutamate excitotoxicity.31 Omega 3 fatty acids—for example, alpha-linolenic acid—have been shown to protect neurones from kainate-induced cell death, probably through ion channels that are

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Mean (SD) levels of premorbid daily nutrient intake in patients and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients with ALS (n = 132)</td>
</tr>
<tr>
<td>Energy intake (MJ/day)</td>
<td>12.3 (4.0)</td>
</tr>
<tr>
<td>Total fat (g)</td>
<td>135.2 (27.6)</td>
</tr>
<tr>
<td>Saturated fat (g)</td>
<td>51.2 (10.5)</td>
</tr>
<tr>
<td>Monounsaturated fat (g)</td>
<td>49.8 (17.2)</td>
</tr>
<tr>
<td>Polyunsaturated fat (g)</td>
<td>25.5 (10.5)</td>
</tr>
<tr>
<td>Cholesterol (mg)</td>
<td>314 (75)</td>
</tr>
<tr>
<td>Flavonols (mg)</td>
<td>24.4 (19.5)</td>
</tr>
<tr>
<td>Lycopene (mg)</td>
<td>4.6 (3.5)</td>
</tr>
<tr>
<td>Glutamate (mg)</td>
<td>826 (382)</td>
</tr>
<tr>
<td>Vitamin C (mg)</td>
<td>133 (69)</td>
</tr>
<tr>
<td>Vitamin E (mg)</td>
<td>17.8 (7.1)</td>
</tr>
<tr>
<td>Riboflavin (mg)</td>
<td>2.0 (0.5)</td>
</tr>
<tr>
<td>Calcium (mg)</td>
<td>1223 (452)</td>
</tr>
<tr>
<td>Phytoestrogens (mg)</td>
<td>0.34 (1.3)</td>
</tr>
<tr>
<td>Dietary supplements n (%)</td>
<td>43 (33)</td>
</tr>
</tbody>
</table>

| Values are energy adjusted according to the residual method. |
also activated by riluzole—the only drug currently effective in ALS. Furthermore, a protective effect of PUFA intake may also suggest a link with cardiovascular disease, similar to Alzheimer’s disease. Chronic hypoperfusion with hypoxia could contribute to mitochondrial dysfunction and motor neurone death in ALS. The recent finding that vascular endothelial growth factor may be implicated in the process of motor neurone degeneration in ALS either reaffirms a defect

### Figure 1

Adjusted ORs for the relationship between amyotrophic lateral sclerosis and (A) the intake of fatty acids and cholesterol and (B) flavonoids, lycopene, glutamate, vitamin C and vitamin E. The ORs were adjusted for sex, age (age at onset for patients), level of education (low, middle, high), smoking (never, ever, current), body mass index (underweight, normal, overweight) and total energy intake according to the residual method; SATFA, saturated fatty acids; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid.
The risk of developing ALS

in neurotrophin biology or suggests a role for chronic hypoxia.

The observed protective effect of vitamin E intake and the risk of developing ALS is in contrast to two previous studies that showed a lack of association.48 In a subsequent large study, however, regular users of vitamin E supplements had a 40–50% reduced risk of developing ALS.46 Also, the observation that vitamin E delays clinical expression in the mouse model of ALS35 and the known inhibitory effects of vitamin E on lipid peroxidation47 support a role for vitamin E in modifying the risk of developing ALS. 4-Hydroxynonenal, a product of lipid peroxidation in vivo, has been shown to be bound to the glutamate transporter in patients with ALS,48 thus damaging the transporter and contributing to glutamate excitotoxicity. The combined analysis, including the interaction term, indicates that vitamin E and PUFAs increase their separate protective effects. Vitamin E may act directly to reduce the risk of ALS as a known inhibitor of lipid peroxidation, but it could also act indirectly through inhibition of peroxidation of nutritional PUFAs. As a result, a higher level of PUFAs will be available biologically. As male sex is an established risk factor and late menarche and early menopause seem to occur in women with ALS,49 intake of phytosterogens was investigated in this study. The intake of phytosterogens was found to be similar in patients and controls.

Premorbid dietary intake of glutamate was previously shown to be higher in patients with ALS,50 suggesting a possible dietary contribution to glutamate excitotoxicity. This study, however, did not show any sign of premorbid increased glutamate intake. Differences in the food-frequency questionnaires that were used probably contributed to this discrepancy. Nevertheless, it is unlikely that dietary intake levels of glutamate are sufficient to cause marked changes in levels of glutamate in the brain and spinal cord, because glutamate levels in the central nervous system are tightly regulated at the blood–brain barrier.51 52

The limitations of this study are the possible influence of overmatching of controls, recall bias and the non-population-based design. Overmatching, however, leads to false-negative findings, further emphasising the positive finding of this study. The effect of recall bias will also be small because patients were not informed about our hypotheses regarding vitamin E or PUFAs, and these data were calculated from general dietary questions. Importantly, this case–control study took into account the possible influence of preclinical disease in assessing dietary intake and adjusted for important confounders, including total energy intake, according to the residual method.53 A population-based case–control study is presently being conducted to generate class I evidence.

ACKNOWLEDGEMENTS

This study was supported by a grant from ZonMW, The Netherlands Organization for Health Research and Development.

Authors’ affiliations
J H Veldink, S Kalmijn, G-J Groeneveld, J van der Luyt, J H J Wokke,
L H Van den Berg, Department of Neurology, Rudolf Magnus Institute of
Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
S Kalmijn, Julius Center for Health Sciences and Primary Care, University
Medical Center Utrecht
W Wunderink, A Koster, J H M de Vries, Department of Human Nutrition,
Wageningen University, The Netherlands
Competing interests: None.

The institutional ethical committee of the University Medical Center
Utrecht approved the study protocol.

REFERENCES

1 Rowland LP. What’s in a name? Amyotrophic lateral sclerosis, motor neuron
2 Ascherio A. An evidence-based medical approach to the evaluation of the role of
3 Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor
control study following detection of a cluster in a small Wisconsin community.
7 Pierce-Ruhland R, Patten BM. Repeat study of antecedent events in motor
20 USDA-Iowa State University Database. http://www.nal.usda.gov/fnic/cgi-
bin/nut_search.pl 1999.
22 Laliger J. Function and importance of glutamate for savory foods. J Nutr 2000;130:915S–20S.
26 Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic
29 Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular
30 Yasojima K, Tourettaffe WW, McGeer EG, et al. Marked increase in
33 Lombrecht DS, Sterkbaeum B, Morimoto M, et al. VEGF is a modifier of
35 Gurney ME, Cutting GB, Zhao P, et al. Benefit of vitamin E, riluzole, and
37 Pedersen WA, Fu W, Keller JN, et al. Protein modification by the lipid